تقيم عوامل نمو الخلايا الليفيه-23 والفوسفات في المرضى العراقيين الذين يعانون من ضخامة الأطراف

Hameed A Sh, Khalee F M, Rahma A M. Superoxide Dismutase and Glutathione S Transferase Enzymes Levels in Diabetic Iraqi Acromegalic Patients. Biochem Cell Arch. 2019; 19(Supplement 1): 2097-2100. https://www.researchgate.net/publication/337758920_SUPEROXIDE_DISMUTASE_AND_GLUTATHIONE_S_TRANSFERASE_ENZYMES_LEVELS_IN_DIABETIC_IRAQI_ACROMEGALIC_PATIENTS#:~:text=10.35124/bca.2019.19.S1.2097

Mahdi RA. Genetic study of AHR exonic part and GNAS intronic part mutations in some of Iraqi acromegalic patients. Endocr abstr. 2019 May;1 (63). https://doi.org/10.1530/endoabs.63.P250

Broersen LH, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR. Improvement in symptoms and health-related quality of life in acromegaly patients. a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021 Feb; 106(2); 577-87. https://doi.org/10.1210/clinem/dgaa868

Abd Aon YS, Kadhim SJ, Al-Samarriae AY. Studying the genotype of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) Gene (rs641081C> A) in‎ Iraqi Samples with Acromegaly Pituitary Adenoma. Baghdad Sci J. 2022 Dec; 1; 19(6): 1167. https://dx.doi.org/10.21123/bsj.2022.1616

- Slagboom TN, van Bunderen CC, De Vries R, Bisschop PH, Drent ML. Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly. A systematic review in accordance with PRISMA guidelines. Pituitary. 2023 May; 20: 1-4. http://dx.doi.org/10.1007/s11102-023-01322-7

Schweizer JR, Schilbach K, Haenelt M, Giannetti AV, Bizzi MF, Soares BS, et al. Soluble alpha klotho in acromegaly. Comparison with traditional markers of disease activity. J Clin Endocrinol Metab. 2021 Aug; 106(8); e2887-99. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277223/#:~:text=%C2%A010.1210/clinem/dgab257

Abass EA, Abed BA, Mohsin SN. Determination of Osteocalcin, Bone Alkaline Phosphatase, and Lysyl Oxidase in Iraqi Acromegalic Patients. Ibn al-Haitham j pure appl sci. 2018 May 17; 31(1); 172-9. https://jih.uobaghdad.edu.iq/index.php/j/article/view/1864#:~:text=DOI%3A-

Hameed AS, Khaleel FM, Rahma AM. The response of acromegalic patients (Diabetic versus non-diabetic) to Long-acting-repeatable Octreotide (LAR) in the presence or absence of Glutathion S transferase (GSTM1, GSTT1) Genes. J Pharm Sci Res. 2018; 10(12): 3090-3094.https://www.jpsr.pharmainfo.in/Documents/Volumes/vol10Issue12/jpsr10121814.pdf

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019 Feb 8; 4(1): 3. https://doi.org/10.1038/s41392-019-0036-y

Kopchick JJ, Berryman DE, Puri V, Lee KY, Jorgensen JO. The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nat Rev Endocrinol. 2020 Mar; 16(3): 135-46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180987/#:~:text=10.1038/s41574%2D019%2D0280%2D9

- Vila G, Jørgensen JO, Luger A, Stalla GK. Insulin resistance in patients with acromegaly. Front Endocrinol. 2019 Jul; 30: 10:509. https://pubmed.ncbi.nlm.nih.gov/31417493/#:~:text=DOI%3A-,10.3389/fendo.2019.00509,-Free%20PMC%20article

Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The biochemical diagnosis of acromegaly. J Clin Med Res. 2021 Mar 9; 10(5):1147 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967116/#:~:text=%C2%A010.3390/jcm10051147

Tahir NT, Abdulsattar SA, Alkazzaz FF. Assessment of Obesity, Dyslipidemia, Hyperglycemia, and Pro-Inflammatory Cytokines as Cardiovascular Disease Risk Factors in Acromegaly Patients. Baghdad Sci J. 2022 Oct 1; 19(5): 0976-http://dx.doi.org/10.21123/bsj.2022.6002

- Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, et al. More than a decade of real-world experience of pegvisomant for acromegaly. Acrostudy. Eur J Endocrinol. 2021 Oct; 185(4): 525-38. https://doi.org/10.1530%2FEJE-21-0239

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BM, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities. an update. J Clin Endocrinol Metab. 2020 Apr 1; 105(4): e937-46. 10.1210/clinem/dgz096 https://doi.org/10.1210/clinem/dgz096

Tönjes A, Quinkler M, Knappe U, Störmann S, Schöfl C, Schopohl J, et al. Treatment of acromegaly-data from the German Acromegaly Register. Dtsch Med. 2023 Mar 20; 148(7): 380-5. https://pubmed.ncbi.nlm.nih.gov/36940688/#:~:text=DOI%3A-,10.1055/a%2D1847%2D2553,-Abstract

Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, et.al. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J Clin Endocrinol Metab 2020 Oct; 105(10): e3785-97. https://pubmed.ncbi.nlm.nih.gov/32882036/#:~:text=DOI%3A-,10.1210/clinem/dgaa526,-Free%20PMC%20article

Gadelha MR, Kasuki L, Lim DS, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019 Feb; 40(1): 268-332. https://pubmed.ncbi.nlm.nih.gov/30184064/#:~:text=DOI%3A-,10.1210/er.2018%2D00115,-Abstract

Zhang L, Qin W. Research progress of fibroblast growth factor 23 in acute kidney injury. Pediatr Nephrol.. 2022 Nov; 22: 1-0. https://doi.org/10.1007/s00467-022-05791-z

-Miyakawa H, Hsu HH, Ogawa M, Akabane R, Miyagawa Y, Takemura N. Serum fibroblast growth factor-23 concentrations in young and mature adult cats with chronic kidney disease. J Feline Med Surg. 2022 Aug; 24(8): 815-20. https://doi.org/10.1177/1098612x211039192

Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol. 2021 Feb; 66(2): R23. 10.1530/JME-20-0178 https://doi.org/10.1530/jme-20-0178

Takir M, Aksu F. Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian J Med Oncol. 2019; 3(1): 14-21. https://dx.doi.org/10.14744/ejmo.2018.0068

Schmid C, Neidert MC, Tschopp O, Sze L, Bernays RL. Growth hormone and Klotho. J. Endocrinol. 2013; 219(2) :R37-57 https://doi.org/10.1530/JOE-13-0285

Clinkenbeard EL, White KE. Systemic control of bone homeostasis by FGF23 signaling. Curr Mol Biol Rep. 2016 Mar; 2: 62-71. http://dx.doi.org/10.1007/s40610-016-0035-5

Lederer E, Wagner CA. Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: mutations and disease associations. Pflugers Arch. 2019 Jan 31; 471(1): 137-48. https://doi.org/10.1007/s00424-018-2246-5

Bär L, Stournaras C, Lang F, Föller M. Regulation of fibroblast growth factor 23 (FGF 23) in health and disease. FEBS Lett. 2019 Aug; 593(15): 1879-900. https://doi.org/10.1002/1873-3468.13494

Haffner D, Grund A, Leifheit-Nestler M. Renal effects of growth hormone in health and in kidney disease. Pediatr Nephrol. 2021 Aug; 36(8): 2511-30. https://doi.org/10.1007/s00467-021-05097-6

Xie T, Tian P, Wu S, Zhang X, Liu T, Gu Y, et al. Serum phosphate: Does it more closely reflect the true state of acromegaly?. J Clin Neurosci. 2020 Jan 1; 71: 26-31. https://doi.org/10.1016/j.jocn.2019.11.012

Rausch S, Föller M. The regulation of FGF23 under physiological and pathophysiological conditions. Pflugers Arch. 2022 Mar; 474(3): 281-92. https://doi.org/10.1007/s00424-022-02668-w

Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020 Jan; 16(1): 7-19. https://doi.org/10.1038/s41581-019-0189-5

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016; 89(1): 135–146. https://doi.org/10.1038/ki.2015.290

Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol. 2019 Feb; 15(2): 109-20 https://doi.org/10.1038/s41581-018-0087-2 .

Yalin GY, Tanrikulu S, Gul N, Uzum AK, Aral F, Tanakol R. Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients. J Endocrinol Invest. 2017 Aug; 40: 867-74. https://doi.org/10.1007/s40618-017-0657-3

Droste M, Domberg J, Buchfelder M, Mann K, Schwanke A, Stalla G, Strasburger CJ. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014 Jul; 171(1): 59-68. https://doi.org/10.1530/eje-13-0438

Li X, Ni X, Chai X, Wang L, Jiang Y, Jing H, et al. Tumor‐induced osteomalacia combined with acromegaly: A case report. Ann N Y Acad Sci. 2022 Nov; 1517(1): 88-92. https://doi.org/10.1111/nyas.14893

Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005 Oct 25; 112(17): 2627-33. https://doi.org/10.1161/circulationaha.105.553198

Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009 Jun 1; 4(6): 1136-9. https://doi.org/10.2215/cjn.01660309

Quarles LD. Endocrine functions of bone in mineral metabolism regulation J Clin Investig. 2008 Dec 1; 118(12): 3820-8. https://doi.org/10.1172/jci36479

Kamenický P, Blanchard A, Gauci C, Salenave S, Letierce A, Lombès M, et al. Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?. J Clin Endocrinol Metab. 2012 Jun 1; 97(6): 2124-33. https://doi.org/10.1210/jc.2011-3188

Bacchetta J, Cochat P, Salusky IB, Wesseling-Perry K. Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol. 2012 Jul; 27: 1131-8. https://doi.org/10.1007%2Fs00467-012-2110-3

Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S, et al. Fibroblast growth factor (FGF) 23 in patients with acromegaly. Endocr J. 2007; 54(3): 481-4. https://doi.org/10.1507/endocrj.k06-217